JP2014519516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519516A5 JP2014519516A5 JP2014514911A JP2014514911A JP2014519516A5 JP 2014519516 A5 JP2014519516 A5 JP 2014519516A5 JP 2014514911 A JP2014514911 A JP 2014514911A JP 2014514911 A JP2014514911 A JP 2014514911A JP 2014519516 A5 JP2014519516 A5 JP 2014519516A5
- Authority
- JP
- Japan
- Prior art keywords
- covalently attached
- ribonucleotides
- positions
- pharmaceutical composition
- moiety covalently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 21
- 239000002336 ribonucleotide Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 230000000692 anti-sense effect Effects 0.000 claims 11
- 208000035657 Abasia Diseases 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 10
- 239000005547 deoxyribonucleotide Substances 0.000 claims 5
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- SBCVJZHHHVYKNM-UHFFFAOYSA-M [2-[bis(2-tetradecanoyloxyethyl)amino]-2-oxoethyl]-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC(=O)OCCN(C(=O)C[N+](C)(C)CCO)CCOC(=O)CCCCCCCCCCCCC SBCVJZHHHVYKNM-UHFFFAOYSA-M 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000002077 nanosphere Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001260 vocal cord Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494832P | 2011-06-08 | 2011-06-08 | |
| US61/494,832 | 2011-06-08 | ||
| US201161497447P | 2011-06-15 | 2011-06-15 | |
| US61/497,447 | 2011-06-15 | ||
| PCT/US2012/041761 WO2012170957A2 (en) | 2011-06-08 | 2012-06-08 | Retinoid-liposomes for enhancing modulation of hsp47 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519516A JP2014519516A (ja) | 2014-08-14 |
| JP2014519516A5 true JP2014519516A5 (enExample) | 2015-07-23 |
| JP5873168B2 JP5873168B2 (ja) | 2016-03-01 |
Family
ID=46395700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514911A Active JP5873168B2 (ja) | 2011-06-08 | 2012-06-08 | Ｈｓｐ４７発現の調節を増強するレチノイド−リポソーム |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8664376B2 (enExample) |
| EP (2) | EP2717921B1 (enExample) |
| JP (1) | JP5873168B2 (enExample) |
| KR (1) | KR102002771B1 (enExample) |
| CN (1) | CN103781909B (enExample) |
| AU (1) | AU2012267472B2 (enExample) |
| CA (1) | CA2836925C (enExample) |
| CY (2) | CY1117683T1 (enExample) |
| DK (2) | DK2717921T3 (enExample) |
| ES (2) | ES2586593T3 (enExample) |
| HR (1) | HRP20181440T8 (enExample) |
| HU (1) | HUE039379T2 (enExample) |
| LT (1) | LT3075855T (enExample) |
| PL (2) | PL2717921T3 (enExample) |
| PT (2) | PT3075855T (enExample) |
| RS (1) | RS57824B1 (enExample) |
| RU (1) | RU2628694C2 (enExample) |
| SI (1) | SI3075855T1 (enExample) |
| SM (1) | SMT201800584T1 (enExample) |
| TW (1) | TWI658830B (enExample) |
| WO (1) | WO2012170957A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) * | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US20160038593A1 (en) * | 2004-12-22 | 2016-02-11 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
| DK2509991T3 (en) | 2009-12-09 | 2015-12-21 | Nitto Denko Corp | MODULATION OF HSP47 EXPRESSION |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| CN107082747B (zh) * | 2011-06-08 | 2020-11-20 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US20140323550A1 (en) * | 2011-11-18 | 2014-10-30 | Nitto Denko Corporation | Intestinal fibrosis treatment agent |
| TR201816986T4 (tr) | 2012-06-08 | 2019-01-21 | Nitto Denko Corp | Terapötik ajan iletim formülasyonlarına yönelik lipitler. |
| EP3116512B1 (en) * | 2014-03-11 | 2020-06-10 | Dai Niann-tzyy | Pharmaceutical composition and method for reducing scar formation |
| CN104174034A (zh) * | 2014-08-20 | 2014-12-03 | 南京大学 | 肝星状细胞靶向的基因药物输送载体及其制备方法和应用 |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| BR112018008344A2 (pt) | 2015-12-13 | 2018-10-30 | Nitto Denko Corp | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição |
| AU2017267634C1 (en) * | 2016-05-16 | 2022-05-26 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
| JP6833456B2 (ja) * | 2016-11-02 | 2021-02-24 | 日東電工株式会社 | 皮膚線維症処置剤 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| WO2018170464A1 (en) * | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Targeted epigenetic therapy against distal regulatory element of tgfb2 expression |
| WO2020181130A2 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| TWI740533B (zh) | 2020-06-11 | 2021-09-21 | 國立中央大學 | 評估個體罹患腹膜硬化症之風險的方法、其分析器及其套組 |
| BR112022026302A2 (pt) * | 2020-06-24 | 2023-01-17 | Bristol Myers Squibb Co | Processo para síntese de moléculas-alvo |
| WO2022040782A1 (en) * | 2020-08-25 | 2022-03-03 | Laurent Pharmaceuticals Inc. | Use of fenretinide or an analogue thereof to treat pulmonary fibrosis |
| JP2025504092A (ja) * | 2022-02-04 | 2025-02-06 | ニューヨーク ユニバーシティ | 心房細動の処置のためのレチノイドの使用 |
| EP4504231A1 (en) | 2022-04-08 | 2025-02-12 | University of North Texas Health Science Center at Fort Worth | Treatment for ocular fibrosis |
| WO2024059714A1 (en) * | 2022-09-15 | 2024-03-21 | Bristol-Myers Squibb Company | Method of treating advanced hepatic fibrosis associated with hcv infection with targeted lipid nanoparticle compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US5811119A (en) | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
| KR970005898B1 (ko) | 1987-09-21 | 1997-04-21 | 젠- 프로우브 인코퍼레이티드 | 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약 |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| EP0618925B2 (en) | 1991-12-24 | 2012-04-18 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| CA2174339A1 (en) | 1993-10-27 | 1995-05-04 | Lech W. Dudycz | 2'-amido and 2'-peptido modified oligonucleotides |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| EP0755454B1 (en) | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
| AU4412096A (en) | 1994-12-13 | 1996-07-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| DE19640092A1 (de) | 1996-09-28 | 1998-04-16 | Beiersdorf Ag | Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind |
| DE19641672A1 (de) | 1996-10-10 | 1998-04-16 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| DE10012151A1 (de) | 2000-03-13 | 2001-09-27 | Gsf Forschungszentrum Umwelt | Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| JP2005507934A (ja) | 2001-10-30 | 2005-03-24 | ネクター セラピューティックス エイエル，コーポレイション | レチノイン酸の水溶性ポリマー結合体 |
| AUPR894201A0 (en) | 2001-11-19 | 2001-12-13 | Women's And Children's Hospital | Respiratory delivery for gene therapy and lentiviral delivery particle |
| PT1527176E (pt) | 2002-08-05 | 2007-04-30 | Atugen Ag | Novas formas de muléculas de arn de interferência |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| JP4755972B2 (ja) | 2003-03-21 | 2011-08-24 | サンタリス ファーマ アー／エス | 短鎖干渉ＲＮＡ（ｓｉＲＮＡ）アナログ |
| WO2004089311A2 (en) | 2003-03-31 | 2004-10-21 | Vectramed, Inc. | Polymeric drug agents for the treatment of fibrotic disorders |
| WO2005040758A2 (en) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| JP2009221164A (ja) * | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| SI2727583T1 (sl) * | 2004-12-22 | 2022-01-31 | Nitto Denko Corporation | Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| EA014886B1 (ru) * | 2006-03-31 | 2011-02-28 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5 |
| DE202006005347U1 (de) * | 2006-04-03 | 2007-08-02 | Efbe Elektrogeräte GmbH | Infrarotleuchte |
| US9074205B2 (en) | 2006-10-18 | 2015-07-07 | Marina Biotech, Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| JP2010527914A (ja) | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| WO2009036368A2 (en) * | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| WO2009059450A1 (en) | 2007-11-05 | 2009-05-14 | Shanghai Jiaotong University | Peptide ligand directed drug delivery |
| KR20110051214A (ko) | 2008-07-30 | 2011-05-17 | 닛토덴코 가부시키가이샤 | 약물 담체 |
| TWI556831B (zh) | 2008-09-12 | 2016-11-11 | 日東電工股份有限公司 | 纖維化疾病之造影劑 |
| KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| DK2509991T3 (en) * | 2009-12-09 | 2015-12-21 | Nitto Denko Corp | MODULATION OF HSP47 EXPRESSION |
| CA3102008A1 (en) * | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| TWI658830B (zh) * | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
-
2012
- 2012-06-07 TW TW101120615A patent/TWI658830B/zh active
- 2012-06-08 US US13/492,639 patent/US8664376B2/en active Active
- 2012-06-08 CN CN201280028300.XA patent/CN103781909B/zh active Active
- 2012-06-08 EP EP12730301.4A patent/EP2717921B1/en active Active
- 2012-06-08 US US13/492,594 patent/US8741867B2/en active Active
- 2012-06-08 JP JP2014514911A patent/JP5873168B2/ja active Active
- 2012-06-08 AU AU2012267472A patent/AU2012267472B2/en not_active Ceased
- 2012-06-08 ES ES12730301.4T patent/ES2586593T3/es active Active
- 2012-06-08 SI SI201231369T patent/SI3075855T1/sl unknown
- 2012-06-08 PL PL12730301.4T patent/PL2717921T3/pl unknown
- 2012-06-08 SM SM20180584T patent/SMT201800584T1/it unknown
- 2012-06-08 DK DK12730301.4T patent/DK2717921T3/en active
- 2012-06-08 HU HUE16169874A patent/HUE039379T2/hu unknown
- 2012-06-08 RU RU2013158469A patent/RU2628694C2/ru active
- 2012-06-08 DK DK16169874.1T patent/DK3075855T3/en active
- 2012-06-08 ES ES16169874.1T patent/ES2689696T3/es active Active
- 2012-06-08 RS RS20181081A patent/RS57824B1/sr unknown
- 2012-06-08 LT LTEP16169874.1T patent/LT3075855T/lt unknown
- 2012-06-08 PT PT16169874T patent/PT3075855T/pt unknown
- 2012-06-08 CA CA2836925A patent/CA2836925C/en active Active
- 2012-06-08 EP EP16169874.1A patent/EP3075855B1/en active Active
- 2012-06-08 KR KR1020147000572A patent/KR102002771B1/ko active Active
- 2012-06-08 PT PT127303014T patent/PT2717921T/pt unknown
- 2012-06-08 WO PCT/US2012/041761 patent/WO2012170957A2/en not_active Ceased
- 2012-06-08 PL PL16169874T patent/PL3075855T3/pl unknown
-
2014
- 2014-06-02 US US14/294,021 patent/US9456984B2/en active Active
-
2016
- 2016-06-17 CY CY20161100543T patent/CY1117683T1/el unknown
- 2016-09-30 US US15/283,179 patent/US10195145B2/en active Active
-
2018
- 2018-09-07 HR HRP20181440TT patent/HRP20181440T8/hr unknown
- 2018-09-11 CY CY20181100947T patent/CY1120685T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519516A5 (enExample) | ||
| US12344841B2 (en) | Chimeric double-stranded nucleic acid | |
| RU2013158469A (ru) | Липосомы с ретиноидом для усиления модуляции экспрессии hsp47 | |
| Quijano et al. | Therapeutic peptide nucleic acids: principles, limitations, and opportunities | |
| Shu et al. | Stable RNA nanoparticles as potential new generation drugs for cancer therapy | |
| CA2917320C (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease | |
| ES2984979T3 (es) | Oligo ARN de doble cadena y composición farmacéutica que comprende el mismo para la prevención o tratamiento de fibrosis o enfermedades respiratorias | |
| JP2014518612A5 (enExample) | ||
| JP2015519047A5 (enExample) | ||
| JP2009544281A5 (enExample) | ||
| Jirka et al. | Peptide conjugation of 2′-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice | |
| JP2014509511A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2019513372A5 (enExample) | ||
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2013544505A (ja) | Ｒｎａ干渉を誘導する核酸分子及びその用途 | |
| JP2017532038A5 (enExample) | ||
| JP2020518552A5 (enExample) | ||
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| CA3089396A1 (en) | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | |
| US11390867B2 (en) | G-quadruplex-containing antisense oligonucleotides | |
| JP2013537404A5 (enExample) | ||
| CN102719432A (zh) | 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用 | |
| JPWO2017043639A1 (ja) | キメラデコイ | |
| JPWO2021167841A5 (enExample) |